Physician profile
Andrei Gasic
NPI 1184623407
$8,642.45
in general payments reported to CMS, 2019-2025
29 companies · $100 in 2025
The $100 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,830 · 2020: $1,206 · 2021: $1,392 · 2022: $2,649 · 2023: $992 · 2024: $473 · 2025: $100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,565.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,922.09 | 2019-2025 | |
| Echosens North America, INC. | $1,084.01 | 2019-2024 | Fibroscan |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $406.64 | 2019-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $390.37 | 2022-2024 | Livdelzi, Epclusa |
| Impulse Dynamics (USA) INC. | $298.15 | 2023-2024 | Optimizer, Optimizer |
| Ambu INC. | $278.40 | 2020-2022 | |
| Medtronic, INC. | $246.56 | 2022-2024 | Bravo |
| Boston Scientific Corporation | $197.79 | 2019-2021 | |
| Steris Corporation | $160.20 | 2020 | |
| Shionogi INC | $155.43 | 2019-2020 | |
| Genzyme Corporation | $142.30 | 2022-2023 | |
| Intercept Pharmaceuticals, INC. | $134.92 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $128.62 | 2023 | Imfinzi |
| Covidien LP | $121.10 | 2020 | |
| Apollo Endosurgery US INC | $107.98 | 2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $106.88 | 2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $97.85 | 2020-2022 | |
| Biotronik INC. | $91.30 | 2020 | |
| Ironwood Pharmaceuticals, INC | $90.42 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $81.30 | 2022-2023 | Dupixent |
| Pfizer INC. | $80.04 | 2019-2021 | |
| Ethicon US, LLC | $77.03 | 2022 | |
| Evoke Pharma, INC. | $60.26 | 2022 | |
| Braintree Laboratories, INC. | $59.51 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $41.62 | 2022 | |
| Bioventus LLC | $22.33 | 2019 | |
| Daiichi Sankyo INC. | $21.57 | 2022 | |
| Merck Sharp & Dohme LLC | $19.92 | 2022 | |
| Celltrion USA INC. | $17.86 | 2024 | Vegzelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrei Gasic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.